Corporate Whistleblower Center Advises Medical Doctors and Pharmaceutical Marketing Reps Who Have Proof of Drug Companies Selling Off-Label Drugs in Any State to Call About Federal Whistleblower Reward Programs

News provided by

Jul 15, 2014, 08:35 ET

WASHINGTON, July 15, 2014 /PRNewswire/ -- The Corporate Whistleblower Center is urging a medical doctor, or pharmaceutical company insider to call them at 866-714-6466, if they have well documented proof a drug company is involved in an off labeling scheme that results in Medicare being overbilled, because the rewards for this type of information really can be substantial. http://CorporateWhistleblowerCenter.Com

Photo - http://photos.prnewswire.com/prnh/20140714/126736

Drug Justice (PRNewsFoto/Corporate Whistleblower Center)

MD (PRNewsFoto/Corporate Whistleblower Center)

Photo - http://photos.prnewswire.com/prnh/20140714/126735

The Corporate Whistleblower Center is urging medical doctors, or drug company marketing representatives to call them at 866-714-6466, if they have well documented proof a drug company is involved in any type of marketing scheme that could end up overbilling Medicare, because the rewards for this type of information can be in the hundreds of thousands, or millions of dollars. http://CorporateWhistleblowerCenter.Com

As an example in April of 2014 the Justice department announced a pharmaceutical company named Astellas Pharma US Inc. will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use.

The settlement resolves allegations that, between 2005 and 2010, Astellas allegedly marketed and promoted the sale of Mycamine for pediatric use, which was not a medically accepted indication and, therefore, not covered by federal health care programs. During this time period, the FDA approved Mycamine to treat adult patients suffering from serious and invasive infections caused by the fungus Candida, including infections in the esophagus, the blood and the abdomen, and to prevent Candida infections in adults undergoing stem cell transplants. From 2005 through June 2013, however, Mycamine was not approved to treat pediatric patients for any use.

The Corporate Whistleblower Center says, "We are convinced pharmaceutical companies are currently involved in off labeling marketing schemes that end up costing Medicare millions of dollars each year. We also firmly believe these types off labeling drug schemes are nationwide in every major city like New York, Los Angeles, Boston, Miami, Dallas, Houston, Chicago, Atlanta, Seattle, Detroit, Saint Louis, and in every state.

"If you are a medical doctor, or drug company sales representative in any state, and you have well documented proof of off labeling prescription drugs please call us anytime at 866-714-6466. Unlike any group in the nation we will help you package your information, and then get you to the nation's top whistleblower attorneys, provided there is enough proof to begin the process." http://CorporateWhistleblowerCenter.Com

The whistleblower in the Astellas settlement will receive $708,852.

Simple rules for a whistleblower from the Corporate Whistleblower Center:

Do not go to the government first, if you are a major whistleblower. The Corporate Whistleblower Center says, "Major whistleblowers frequently go to the federal government thinking they will help. It's a huge mistake. Frequently government officials could care less, or they are incompetent."
Do not go to the news media with your whistleblower information. Public revelation of a whistleblower's information could destroy any prospect for a reward.
Do not try to force a government contractor, or corporation to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, "Fraud is so rampant among federal contractors, that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. We say, come to us first, tell us what type of information you have, and if we think its sufficient, we will help find the right law firms, to assist in advancing your information."

The Corporate Whistleblower Center wants to emphasize there are high quality whistleblowers in every state including California, New York, Florida, Texas, Massachusetts, Maryland, Virginia, Ohio, Pennsylvania, North Carolina, Georgia, Alabama, Louisiana, Oklahoma, Missouri, Michigan, Indiana, Illinois, Wisconsin, Minnesota, Nebraska, Kansas, Colorado, Utah, New Mexico, Arizona, Nevada, Oregon, Washington, and Alaska.

Any type of insider, or employee, who possesses significant proof of their employer, or a government contractor fleecing the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466, or they can contact the group via their web site at http://CorporateWhistleBlowerCenter.Com.

For attribution purposes please refer to the April 2014 United States Department of Justice press release. http://www.justice.gov/opa/pr/2014/April/14-civ-391.html

The lawsuit is captioned United States ex rel. Smith v. Astellas Pharma, US Inc. et al., No. 10-999 (E.D. Pa.).

Media Contact:
M. Thomas Martin
866-714-6466

SOURCE Corporate Whistleblower Center